This site is intended for U.S. healthcare providers only.

3 REASONS

1 SOMATULINE® DEPOT

(lanreotide) Injection 120 mg

The 1st and only SSA that is FDA-approved to treat1:

  • adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival; and
  • adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy

SSA=somatostatin analog; PFS=progression-free survival.

1 PFS in Patients With GEP‑NETs Read More

 

2 Carcinoid Syndrome Read More